Protective Effects of Genistein on Myocardial Injury in Diabetic Rats
Abstract
To investigate the effects of genistein (Gen) on myocardial injury in diabetic rats and explore its mechanisms. Methods Male SD rats were randomly divided into normal (N) group, diabetic (D) group, Gen 5 mg/kg treatment (L) group and Gen 25 mg/kg treatment (H) group (n=8 for each group). Intraperitoneal injection of streptozotocin was utilized to establish type 1 diabetic rat model. After successful building models, from the fifth week, the rats in the L and H groups were daily gavaged with 5 mg/kg and 25 mg/kg Gen solution, respectively. After 4 weeks of treatment with Gen, the hemodynamic parameters and fasting blood glucose (FBG) level were measured. The morphological structure and ultrastructure of myocardium were observed using HE staining and transmission electron microscopy, respectively. The levels of tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), interleukin-6 (IL-6), malondialdehyde (MDA), glutathione (GSH) and Caspase-3 in myocardial tissue were measured. The levels of myocardial Bcl-2 and Bax at mRNA expression were detected using RT-PCR. The levels of myocardial thioredoxin (Trx), Trx-interacting protein (TXNIP) and apoptosis signal regulating kinase 1 (ASK1) at protein expression were detected using Western blot. Results Compared with the N group, the FBG, TNF-α, IL-1β, IL-6, MDA and Caspase-3 levels were increased (P<0.01), while hemodynamic parameters and GSH content were decreased (P<0.01), the myocardial morphological structure and ultrastructure were damaged in the D group. The levels of Bcl-2 mRNA and Trx protein expression were significantly decreased (P<0.01), while the levels of Bax mRNA, TXNIP and ASK1 protein expression were significantly increased (P<0.01) in the D group. Compared with the D group, in the L and H groups, there was no significant difference in FBG, the TNF-α, IL-1β, IL-6, MDA and Caspase-3 levels were decreased (P<0.05, P<0.01), while the hemodynamic parameters and GSH content were increased (P<0.05, P<0.01); the myocardial morphological structural and ultrastructural damages were alleviated; the levels of Bcl-2 mRNA and Trx protein expression were increased (P<0.05, P<0.01), while the levels of Bax mRNA, TXNIP and ASK1 protein expression were significantly decreased (P<0.05, P<0.01). Conclusion Gen exhibits a protective effect on myocardial injury in diabetic rats, and the mechanisms may be associated with the reduction of inflammatory reaction, the regulation of Trx system expression, and the inhibition of oxidative stress and cell apoptosis.
Keywords: Genistein, Diabetes mellitus, Myocardium, Thioredoxin, Oxidative stress, Cell apoptosis
Full Text:
PDFReferences
ZHANG X, CHEN С. A new insight of mechanisms, diagnosis and treatment of diabetic cardiomyopathy. Endocrine ,2012,41(3): 398-409.
FALCAO PI, LEITE-MOREIRA AF. Diabetic cardiomyopathy; understanding the molecular and cellular basis to progress in diagnosis and treatment. Heart Fail Rev, 2012,17(3):325-344.
DIXON RA, FERREIRA D. Genistein. Phytochemistry, 2002,60(3):205-211.
ELMARAKBY AA, IBRAHIM AS, FAULKNER J, et al. Tyrosine kinase inhibitor, genistein, reduces renal inflammation and injury in streptozotocin-induced diabetic mice. Vascul Pharmacol,2011 ,55(5/6); 149-156.
KIM MJ, LIM Y. Protective effect of short-term genistein supplementation on the early stage in diabetes-induced renal damage. Mediators Inflamm. 2013 ; 510212 [ 2018-03-02 ]. http://dx. doi. org/10. 1155/2013/510212.
GUPTA SK, DONGARE S, MATHUR R, et al. Genistein ameliorates cardiac inflammation and oxidative stress in streptozotocin-induced diabetic cardiomyopathy in rats. Mol Cell Biochem, 2015,408( 1 /2): 63-72.
SUNG MJ, KIM DH, JUNG YJ, et al. Genistein protects the kidney from cisplatin-induced injury. Kidney Int,2008.74 (12):1538-1547.
BUGGER H. ABEL El). Molecular mechanisms of diabetic cardiomyopathy. Diabetologia«2014 *57(4): 660-671. EXNERM, HERMANN M, HOFBAUER R. et al. Genistein prevents the glucose autoxidation mediated atherogenic modification of low density lipoprotein. Free Radic Res,2001,34(1); 101-112.
MAHMOOD DF. ABDERRAZAK A, EL HADRI K. etal. The thioredoxin system as a therapeutic target in human health and disease. Antioxid Redox Signal. 2013, 19(11): 1266-1303.
MANOHARANR, SEONG HA. HA H. Thioredoxin inhibits MPK38- induced ASK1, TGF-j3, and p53 function in a phosphorylation-dependent manner. Free Radic Biol Med. 2013,63(5):313-324.
JUNG H. SEONG HA, HA H. Murine protein serine/ threonine kinase 38 activates apoptosis signal-regulating kinase 1 via Thr 838 phosphyorylationp. J Biol Chem.2008. 283(50):34541-34553.
HWANG J, SUH HW. JEON YH, et al. The structural basis for the negative regulation of thioredoxin by thioredoxin-interacting protein. Nat Commun, 2014 , 5; 2958 [ 2018-03-02 ]. https;//www. nature. com/articles/ ncomms3958. doi;10. 1038/ncomms3958.
YOSHIHARA E, MASAKI S, MATSUO Y, et al. Thioredoxin/Txnip: redoxisome, as a redox switch for the pathogenesis of diseases. Front Immunol.2014,4: 514[2018- 03-02]. https://doi. org/10. 3389/fimmu. 2013. 00514.
CHONG CR. CHAN WP. NGUYEN TH. et al. Thioredoxin-interacting protein: pathophysiology and emerging pharmacotherapeutics in cardiovascular disease and diabetes. Cardiovasc Drugs Ther.2014,28(4) :347-360.
ZHAO X. ZHANG Y, LI X. et al. Variations of thioredoxin system contributes to increased susceptibility to apoptosis in cardiomyocytes of type 2 diabetic rats. Acta Biochim Biophys Sin,2014,46(4) ;318-329.
REN X. MA H, QIU Y, et al. The downregulation of thioredoxin accelerated Neuro2a cell apoptosis induced by advanced glycation end product via activating several pathways. Neurochem Int,2015,87;128-135.
Refbacks
- There are currently no refbacks.



